Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches
Contents
Chair
Prof. Ralf Weiskirchen
The head of the Institute of Molecular Pathobiochemistry, Experimental Gene Therapy, and Clinical Chemistry (IFMPEGKC) at the RWTH University Hospital Aachen, Germany.
Moderator
Assoc. Prof. Gyorgy Baffy
- Department of Medicine, VA Boston Healthcare System and Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
- Associate Professor of Medicine at Harvard Medical School and Chief of Gastroenterology at the VA Boston Healthcare System.
Speaker(s)
Prof. Wolfgang Stremmel
Medical Center Baden-Baden, Baden-Baden, Germany.
Dr. Mohamad Jamalinia
Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Iran.
Prof. Alessandro Mantovani
Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy.
Dr. Shelley Keating
School of Human Movement and Nutrition Sciences, The University of Queensland, Brisbane, Australia.
Asst. Prof. Thomas Jensen
- Division of Endocrinology, University of Colorado, Denver, CO, USA.
- Co-Director NAFLD Multidisciplinary Team.
- Director of Diabetes and Metabolic Medicine for Transplant.
Programme
Programme
| Time (GMT-2, Germany) | Chair/Moderator/Speakers | Topic |
| 04:00 PM - 04:05 PM | Ralf Weiskirchen | Introduction: etiology, burden and clinical spectrum of liver fibrosis |
| Session 1 – Pathobiology and diagnosis | ||
| 04:05 PM - 04:20 PM | Wolfgang Stremmel | Low phosphatidylcholine in biliary mucus as pathogenetic factor in primary sclerosing cholangitis (PSC), the genuine fibrotic disease of the biliary tract? |
| 04:20 PM - 04:35 PM | Coming soon | Coming soon |
| Session 2 – Clinical spectrum | ||
| 04:35 PM - 04:50 PM | Mohamad Jamalinia | Impact of Liver Fibrosis on Cardiovascular Risk: Prognostic Insights and Limitations |
| 04:50 PM - 05:05 PM | Alessandro Mantovani | Role of Liver Fibrosis in the Progression of Chronic Kidney Disease |
| 05:05 PM - 05:20 PM | Coming soon | Liver Fibrosis and Cancer |
| Session 3 – Management options | ||
| 05:20 PM - 05:35 PM | Shelley Keating | Exercise for Fibrosis/Fibroinflammation in MASLD |
| 05:35 PM - 05:50 PM | Thomas Jensen | Drug treatment of liver fibrosis |
| Session 4 – Presentation of the Journal, general discussion, and concluding remarks | ||
| 05:50 PM - 06:00 PM | M&TOD Editorial Office | Presentation of M&TOD |
| 06:00 PM - 06:10 PM | Gyorgy Baffy | Q&A |
| 06:10 PM - 06:15 PM | Ralf Weiskirchen | Concluding remarks |
